Pharma ROI highest since 2014, Deloitte study says

12 January 2022

Projected return on investment (ROI) in research and development (R&D) for 15 global pharma companies – including the 12 largest by market cap – have risen to 7% in 2021, the highest level since 2014, according to research by Deloitte’s Centre for Health Solutions.

This is an increase of 4.3% compared to 2020, the largest annual rise since the study began.

Forecast average peak sales per asset are $521 million, the highest level in four years and significantly greater than $422 million in 2020, driven partly by the sales forecasts for emergency-approved COVID-19 vaccinations and treatments to the mass-market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK